ホーム › アルツハイマー病 › フロリダ州 › Miami
Miami、FLにおけるアルツハイマー病の臨床試験
Miamiとその周辺地域（約30マイル以内）の拠点で、アルツハイマー病に関する20件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
被験者募集中第2相
- Clinical Site, Miami
- Clinical Site, Miami
- Clinical Site, Miami
- 他1件
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
被験者募集中第2相
- Allied Biomedical Research Institute (ABRI), Inc, Miami
- South Florida Research Phase I-IV, Miami
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
被験者募集中第3相
- Nuovida Research Center, Miami
A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)
被験者募集中第4相
- Allied Biomedical Research Institute (ABRI), Inc, Miami
- CCM Clinical Research Group, LLC, Miami
Combating Alzheimer's Through Sleep and Exercise
被験者募集中健康なボランティア歓迎
- University of Miami Hospitals, Miami
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
被験者募集中第2相
- BRP-Kendal Lakes, Miami
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
被験者募集中第3相
- Visionary Investigators Network- Neurology Aventura, Miami
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
被験者募集中第3相
- Local Institution - 1602, Miami
- Local Institution - 1618, Miami
- Hope Research Network - Miami, Miami
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
被験者募集中第3相
- Miami Jewish health, Miami
- Local Institution - 2637, Miami
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
被験者募集中第3相
- University of Miami, Miami
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
被験者募集中第3相
- Finlay Medical Research, Miami
- VIN-Andrew Lerman, Miami
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.
被験者募集中第2相
- University of Miami Department of Neurology, Miami
Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.
被験者募集中第2相
- University of Miami Department of Neurology, Miami
[18F]PI-2620 Phase 3 Histopathological Study
被験者募集中第3相
- Miami Jewish Health Systems, Miami
Late Onset Alzheimer's Disease
被験者募集中観察研究健康なボランティア歓迎
- University of Miami, Miami
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
被験者募集中観察研究健康なボランティア歓迎
- Visionary Investigators Network, Miami
Open-label Extension Study in Participants With Early Alzheimer's Disease
被験者募集中第2相
- GSK Investigational Site, Miami
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
被験者募集中
- Baptist Health South Florida & Florida International University, Miami
Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy
被験者募集中観察研究健康なボランティア歓迎
- Andrey Vyshedskiy, Miami
Longitudinal Cognitive Assessment by BoCA
被験者募集中観察研究健康なボランティア歓迎
- Andrey Vyshedskiy, Miami
他の都市におけるアルツハイマー病の試験
- Boston, MA26件の研究
- Orlando, FL25件の研究
- St. Louis, MO22件の研究
- New York City, NY21件の研究
- Tampa, FL17件の研究
- Atlanta, GA16件の研究
- The Villages, FL15件の研究
- Philadelphia, PA15件の研究
- Phoenix, AZ15件の研究
- Indianapolis, IN14件の研究
- Los Angeles, CA14件の研究
- West Palm Beach, FL13件の研究
Miamiにおける他の研究
- 乳がん42件の研究
- がん（全種類）36件の研究
- 非小細胞肺癌31件の研究
- 前立腺がん27件の研究
- 肥満症27件の研究
- 急性骨髄性白血病24件の研究
- 転移性癌23件の研究
- 過体重23件の研究
- 卵巣がん23件の研究
- 潰瘍性大腸炎21件の研究
- 多発性骨髄腫21件の研究
- 肺がん20件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。